BioCryst Pharmaceuticals, Inc.
BCRX
$8.80
$0.222.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -721.81M | 245.85M | 12.90M | 5.09M | 32.00K |
| Total Depreciation and Amortization | 1.06M | 854.00K | 1.97M | 329.00K | 331.00K |
| Total Amortization of Deferred Charges | 149.00K | -- | -- | -- | 544.00K |
| Total Other Non-Cash Items | 730.21M | 41.03M | 28.12M | 33.51M | 33.71M |
| Change in Net Operating Assets | -71.40M | 4.23M | -1.37M | 2.38M | -62.13M |
| Cash from Operations | -61.79M | 291.96M | 41.62M | 41.30M | -27.52M |
| Capital Expenditure | -403.00K | -802.00K | -1.34M | -179.00K | -143.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 550.00K | -- | -- |
| Cash Acquisitions | -489.48M | -- | -- | -- | -- |
| Divestitures | -- | -6.18M | -- | -- | -- |
| Other Investing Activities | 221.24M | -76.50M | 14.37M | 29.31M | 27.24M |
| Cash from Investing | -268.65M | -83.49M | 13.57M | 29.13M | 27.10M |
| Total Debt Issued | 400.00M | -- | -- | -- | -- |
| Total Debt Repaid | -821.00K | -197.14M | -60.85M | -76.25M | -516.00K |
| Issuance of Common Stock | 19.51M | 680.00K | 2.67M | 3.43M | 2.40M |
| Repurchase of Common Stock | -1.19M | -6.00M | -628.00K | -866.00K | -1.35M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4.95M | -15.50M | -- | -- | -- |
| Cash from Financing | 412.55M | -217.96M | -58.81M | -73.69M | 529.00K |
| Foreign Exchange rate Adjustments | -72.00K | -72.00K | -468.00K | 1.36M | 451.00K |
| Miscellaneous Cash Flow Adjustments | -- | 14.84M | 218.00K | -15.06M | -- |
| Net Change in Cash | 82.04M | 5.28M | -3.87M | -16.96M | 558.00K |